Vaccination with messenger RNA (mRNA)

Area of Science:

• Molecular Biology
• Immunology
• Vaccinology

Background:

• Foreign nucleic acids, including DNA and mRNA, can trigger immune responses via Toll-like Receptors (TLRs).
• DNA-based vaccines have faced challenges in human approvals, prompting exploration of alternative nucleic acid platforms.

Purpose of the Study:

• To evaluate messenger RNA (mRNA) as a gene vaccination vehicle.
• To explore optimized mRNA structures and delivery methods for enhanced immunogenicity.
• To review clinical trial data on mRNA-based vaccines.

Main Methods:

• Optimization of mRNA for codon usage, stability, and antigen presentation.
• Investigated various delivery systems: naked mRNA, liposomes, particle coatings, and in vitro dendritic cell transfection.
• Analysis of preclinical and clinical trial data.

Main Results:

• Optimized mRNA demonstrated potent gene vaccination capabilities across different delivery methods.
• Human clinical trials confirmed that mRNA delivery induces antigen-specific immune responses.
• mRNA production is scalable under Good Manufacturing Practice (GMP) conditions.

Conclusions:

• mRNA represents a promising and potentially safer alternative to DNA for vaccine development.
• Further clinical studies are ongoing to assess the efficacy of mRNA-based vaccines.
• The scalability and GMP production of mRNA support its advancement in therapeutic applications.